• Protalix BioTherapeutics’ third-quarter 2026 net income rose 68% year over year to $3.96 million.
• Revenue climbed 23% year over year to $21.93 million in the quarter.
• Enrollment continues in the PRX-115 Phase 2 RELEASE study for uncontrolled gout, with top-line results expected in the second half of 2027.
• Management expects to meet or exceed 2026 revenue guidance of approximately $78 million to $83 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611100645PR_NEWS_USPR_____IO92475) on November 10, 2026, and is solely responsible for the information contained therein.